Addition of Magnesium Sulfate to Caudal to Prevent Postoperative Emergence Agitation.

Sponsor
Ain Shams University (Other)
Overall Status
Unknown status
CT.gov ID
NCT02164773
Collaborator
(none)
70
1
2
10
7

Study Details

Study Description

Brief Summary

Emergence agitation after sevoflurane anesthesia is still a problem needed to be solved.The aim of the study is to delineate the effect of caudal magnesium sulfate in children undergoing lower abdominal surgery to prevent postoperative emergence agitation.

Condition or Disease Intervention/Treatment Phase
  • Drug: Magnesium Sulfate
  • Drug: 0.9%normal saline
Phase 4

Detailed Description

Emergency agitation is considered one of the postoperative complication after sevoflurane anesthesia.In the enrollment of this study,children undergoing lower abdominal surgery will be enrolled in one of two groups.BM group, receive caudal magnesium sulfate 50 mg beside the conventional bupivacaine in the caudal space in ,B group, addition of 1 ml of normal saline0.9% to bupivacine .Monitoring of the postoperative emergence agitation by different emergence agitation scores with monitoring of sedation score.Detection of expected postoperative complications as nausea and vomiting.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
70 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Care Provider)
Primary Purpose:
Prevention
Official Title:
Addition of Magnesium Sulfate to Caudal for Prevention of Emergence Agitation in Children
Study Start Date :
Oct 1, 2013
Anticipated Primary Completion Date :
Jul 1, 2014
Anticipated Study Completion Date :
Aug 1, 2014

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: magnesium sulfate

magnesium sulfate 50mg caudal 1ml(5%) prepared after addition of 9ml of 0.9%normal saline to 1ml of 500mg(50%)of magnesium sulfate to be added to 1ml/kg of 0.25%of bupivacaine in caudal block in children undergoing lower abdominal surgery under sevoflurane anesthesia to prevent emergence agitation.

Drug: Magnesium Sulfate
use of 50mg magnesium sulfate in caudal analgesia added to 1ml/kg of 0.25% of bupivacaine in children undergoing lower abdominal surgery for prevention of postoperative emergence agitation.

Placebo Comparator: o.9%normal saline

0.9% of normal saline added to the conventional 0.25% bupivacaine in caudal block.

Drug: 0.9%normal saline
use of 1ml of 0.9%normal saline added to 1ml/kg of 0.25% of bupivacaine in the caudal block as placebo to compare with active comparator.

Outcome Measures

Primary Outcome Measures

  1. measure of postoperative pediatric anesthesia emergence delirium PAED score [first 30 minutes postoperative]

    measurement of PAED score every 5 minutes in the first 30 minutes after lower abdominal surgery in children 1-6 year age after sevoflurane anesthesia.

Secondary Outcome Measures

  1. measure of postoperative sedation score. [the first 30 minutes postoperatively]

    use of sedation score as a measure of postoperative sedation expected after caudal magnesium sulfate every 5 minutes for 30 minutes after end of surgery.

Other Outcome Measures

  1. postoperative rescue propofol intravenous 1mg/kg in cases if agitation [first 30 minutes postoperative]

    if emergence agitation occur giving of 1mg/kg of intravenous propofol as rescue medication

Eligibility Criteria

Criteria

Ages Eligible for Study:
1 Year to 6 Years
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • children undergoing lower abdominal surgery for hernia repair/orchiopexy in Ain Shams University ASA physical status I under sevoflurane anesthesia.

  • age from 1-6 years.

Exclusion Criteria:
  • children with developmental delay

  • neurological disorder.

  • psychological disorder

  • difficult airway

  • hyperactive airway disease

  • contraindication to caudal block(sacral abnormality,bleeding disorder).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ain Shams University Cairo Egypt 11566

Sponsors and Collaborators

  • Ain Shams University

Investigators

  • Study Director: Alaa Elkateb, MD, Ain Shams University

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
Ashraf Elsayed Elagamy, ashraf elagamy, Ain Shams University
ClinicalTrials.gov Identifier:
NCT02164773
Other Study ID Numbers:
  • use of magnesium sulfate
First Posted:
Jun 17, 2014
Last Update Posted:
Jun 17, 2014
Last Verified:
Jun 1, 2014

Study Results

No Results Posted as of Jun 17, 2014